Why the study?
This study evaluated the diagnostic performance of plasma biomarkers for Alzheimer's disease using an automated platform.
Does plasma p-Tau181 testing accurately diagnose Alzheimer's disease in clinical patients?
Does plasma p-Tau181 testing accurately diagnose Alzheimer's disease in clinical patients?
Plasma p-Tau181 offers a less invasive and cost-effective alternative to traditional methods for Alzheimer's disease diagnostics.
Should not yet change AD diagnostic pathways; extends plasma p-Tau181 evidence but requires prospective validation.
This study evaluated the diagnostic performance of plasma biomarkers for Alzheimer's disease (AD) using an automated platform. In a cohort of 74 consecutive patients, plasma p-Tau181 levels were significantly higher in AD compared to non-AD groups and showed correlation with cerebrospinal fluid biomarkers. Plasma p-Tau181 demonstrated high diagnostic accuracy for AD, with an area under the curve of 0.854. The findings suggest that plasma biomarkers, particularly p-Tau181, could improve the accessibility and efficiency of AD diagnostics in clinical settings, offering a less invasive and cost-effective alternative to traditional methods.
No takes yet. Share an insight, caveat, or question.
Roveta et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: